World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial

In two back-to-back essays, we and our counterparts reach opposing conclusions regarding the DART trial and broad reimbursement of dual immunotherapy.